DK1526134T3 - Triazolyltropanderivater som CCR5-modulatorer - Google Patents

Triazolyltropanderivater som CCR5-modulatorer

Info

Publication number
DK1526134T3
DK1526134T3 DK04004193T DK04004193T DK1526134T3 DK 1526134 T3 DK1526134 T3 DK 1526134T3 DK 04004193 T DK04004193 T DK 04004193T DK 04004193 T DK04004193 T DK 04004193T DK 1526134 T3 DK1526134 T3 DK 1526134T3
Authority
DK
Denmark
Prior art keywords
triazolyltropane
derivatives
ccr5 modulators
ccr5
modulators
Prior art date
Application number
DK04004193T
Other languages
English (en)
Inventor
Manoussos Perros
David Anthony Price
Blanda Luzia Christa Stammen
Anthony Wood
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0014046A external-priority patent/GB0014046D0/en
Priority claimed from GB0015835A external-priority patent/GB0015835D0/en
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK1526134T3 publication Critical patent/DK1526134T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
DK04004193T 2000-05-26 2001-05-09 Triazolyltropanderivater som CCR5-modulatorer DK1526134T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0014046A GB0014046D0 (en) 2000-05-26 2000-05-26 Compounds useful in therapy
GB0015835A GB0015835D0 (en) 2000-06-27 2000-06-27 Compounds useful in therapy
PCT/IB2001/000806 WO2001090106A2 (en) 2000-05-26 2001-05-09 Tryasolyl tropane derivatives as ccr5 modulators

Publications (1)

Publication Number Publication Date
DK1526134T3 true DK1526134T3 (da) 2008-11-17

Family

ID=26244452

Family Applications (2)

Application Number Title Priority Date Filing Date
DK01925808T DK1284974T3 (da) 2000-05-26 2001-05-09 Triazolyltropanderivater som CCR5-modulatorer
DK04004193T DK1526134T3 (da) 2000-05-26 2001-05-09 Triazolyltropanderivater som CCR5-modulatorer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK01925808T DK1284974T3 (da) 2000-05-26 2001-05-09 Triazolyltropanderivater som CCR5-modulatorer

Country Status (51)

Country Link
EP (3) EP1526134B1 (da)
JP (2) JP3693957B2 (da)
KR (2) KR100548854B1 (da)
CN (2) CN1279040C (da)
AP (1) AP1965A (da)
AR (2) AR028622A1 (da)
AT (2) ATE260914T1 (da)
AU (2) AU5248201A (da)
BG (1) BG65966B1 (da)
BR (1) BRPI0110955B8 (da)
CA (1) CA2408909C (da)
CR (1) CR10145A (da)
CU (1) CU23288B7 (da)
CY (2) CY2008006I2 (da)
CZ (1) CZ299102B6 (da)
DE (3) DE122008000011I1 (da)
DK (2) DK1284974T3 (da)
DZ (1) DZ3464A1 (da)
EA (2) EA005382B1 (da)
EE (1) EE05110B1 (da)
EG (1) EG24137A (da)
ES (3) ES2215129T3 (da)
FR (1) FR08C0007I2 (da)
GE (1) GEP20063799B (da)
HK (3) HK1054927A1 (da)
HR (1) HRP20020938B1 (da)
HU (1) HU225810B1 (da)
IL (2) IL152531A0 (da)
IS (1) IS2511B (da)
LT (1) LTC1284974I2 (da)
LU (1) LU91417I2 (da)
MA (1) MA26902A1 (da)
ME (1) ME00555B (da)
MX (1) MXPA02011631A (da)
MY (3) MY153023A (da)
NL (1) NL300338I2 (da)
NO (3) NO327892B1 (da)
NZ (1) NZ521477A (da)
OA (1) OA12264A (da)
PA (1) PA8517101A1 (da)
PE (1) PE20011371A1 (da)
PL (1) PL200551B1 (da)
PT (2) PT1284974E (da)
RS (2) RS51436B (da)
SI (2) SI1284974T1 (da)
SK (1) SK286129B6 (da)
TN (1) TNSN01077A1 (da)
TR (1) TR200400541T4 (da)
TW (1) TWI230160B (da)
UY (1) UY26727A1 (da)
WO (1) WO2001090106A2 (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100548854B1 (ko) * 2000-05-26 2006-02-02 화이자 인코포레이티드 Ccr5 조절제로서의 트리아졸릴 트로판 유도체
JP2004537531A (ja) * 2001-06-12 2004-12-16 エスケー コーポレイション 新規フェニルアルキルジアミンおよびアミド類似体
SE0200919D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Chemical compounds
US6855724B2 (en) 2002-04-08 2005-02-15 Agouron Pharmaceuticals, Inc. Tropane derivatives useful in therapy
GB0208071D0 (en) * 2002-04-08 2002-05-22 Pfizer Ltd Tropane derivatives useful in therapy
WO2003084954A1 (en) * 2002-04-08 2003-10-16 Pfizer Limited Tropane derivatives as ccr5 modulators
AU2003230129A1 (en) * 2002-05-23 2003-12-12 Pfizer Inc. Method for identification of a ligand whereby receptor residence time is measured
ATE405269T1 (de) * 2002-12-13 2008-09-15 Smithkline Beecham Corp Cyclohexylverbindungen als ccr5-antagonisten
DE10336274A1 (de) * 2003-08-07 2005-03-10 Honeywell Specialty Chemicals Verfahren zur Herstellung von geminalen Difluoralkanen
BRPI0413330A (pt) 2003-08-29 2006-10-10 Ranbaxy Lab Ltd inibidores de fosfodiesterase do tipo iv, composição farmacêutica contendo os mesmos e processo para sua preparação
EP1786816A4 (en) 2003-09-10 2009-11-04 Virochem Pharma Inc SPIROHYDANTOIN COMPOUNDS AND METHODS FOR MODULATING CHEMOKINE RECEPTOR ACTIVITY
US7309790B2 (en) * 2003-10-03 2007-12-18 Pfizer Inc Chemical compounds
TW200610761A (en) 2004-04-23 2006-04-01 Astrazeneca Ab Chemical compounds
PT1761542E (pt) 2004-06-09 2008-03-26 Hoffmann La Roche Derivados de octa-hidro-pirrolo[3,4-c) pirrole e o seu uso com agentes antivirais
EP1814549A2 (en) * 2004-11-19 2007-08-08 Boehringer Ingelheim International GmbH Method for treating hiv infection through co-administration of tipranavir and uk-427, 857
WO2006064340A2 (en) * 2004-12-13 2006-06-22 Pfizer Limited Process for the preparation of n-acyl beta-aminoaldehydes
US7665658B2 (en) 2005-06-07 2010-02-23 First Data Corporation Dynamic aggregation of payment transactions
CA2616189C (en) 2005-07-22 2019-03-26 Progenics Pharmaceuticals, Inc. Methods for reducing viral load in hiv-1-infected patients
EP1940781A1 (en) 2005-10-19 2008-07-09 F.Hoffmann-La Roche Ag Phenyl-acetamide nnrt inhibitors
MX2009001198A (es) 2006-08-16 2009-02-11 Hoffmann La Roche Inhibidores no nucleosidicos de la transcriptasa inversa.
WO2008063600A2 (en) * 2006-11-17 2008-05-29 Concert Pharmaceuticals Inc. Triazolyl tropane derivatives
WO2008071587A2 (en) 2006-12-13 2008-06-19 F. Hoffmann-La Roche Ag 2-(piperidin-4-yl)-4-phenoxy- or phenylamino-pyrimidine derivatives as non-nucleoside reverse transcriptase inhibitors
AU2007333667A1 (en) * 2006-12-19 2008-06-26 Auspex Pharmaceuticals, Inc. Preperation and utility of CCR5 inhibitors
EP1958947A1 (en) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type 4
WO2008132128A2 (en) * 2007-04-27 2008-11-06 Solvay (Société Anonyme) Synthesis of a pharmaceutically active compound
CA2716838C (en) * 2008-02-29 2014-01-07 Schering Corporation Ccr5 antagonists as prophylactics for preventing hiv infection and methods of inhibiting transmission of same
CN101712679B (zh) * 2008-10-08 2013-04-10 中国科学院上海药物研究所 一种酰胺类化合物、其药物组合物及其制备方法和用途
EP2456309B1 (en) * 2009-07-24 2015-12-23 GlaxoSmithKline LLC Azabicyclo[3.2.1]octyl derivatives for use in the treatment of HIV.
CN102140104B (zh) * 2010-02-03 2014-11-12 中国科学院上海药物研究所 1-(3-(s)-氨基丙基)-哌啶-4-氨基酰胺类化合物、其药物组合物及其制备方法和用途
MX2012011415A (es) 2010-04-02 2013-02-26 Phivco 1 Llc Terapia de combinacion que comprende un antagonista de ccr5, un inhibidor de proteasa de vih-1, y un potenciador farmacocinetico.
CN103159754A (zh) * 2011-12-19 2013-06-19 中国科学院上海药物研究所 一种氨基丙基取代托烷胺类化合物、其药物组合物及其制备方法和用途
JP2015536940A (ja) 2012-10-29 2015-12-24 シプラ・リミテッド 抗ウイルス性ホスホネート類似体及びその製造方法
CZ306455B6 (cs) 2013-04-26 2017-02-01 Zentiva, K.S. Nový způsob syntézy Maravirocu
CN103497164B (zh) * 2013-09-23 2015-12-23 西安近代化学研究所 一种蒽衍生物及其制备方法
CN104304248B (zh) * 2014-10-23 2016-08-10 西北农林科技大学 3-芳基丙酸酯类化合物作为制备杀螨药物的应用
CN104402883B (zh) * 2014-10-24 2016-04-27 艾琪康医药科技(上海)有限公司 4,4-二氟金刚烷甲酰胺衍生物、药物组合物及其制备方法和用途
CN104387379B (zh) * 2014-11-26 2017-01-11 扬州氟药科技有限公司 一种二氟亚甲基哌啶甲酰胺衍生物及其制备方法和用途
CN104860946A (zh) * 2015-05-14 2015-08-26 湖北生物医药产业技术研究院有限公司 Ccr5拮抗剂的制备方法
CN107879963A (zh) * 2016-09-29 2018-04-06 中国科学院上海药物研究所 新型手性配体、金属螯合物、多种非天然氨基酸、马拉维诺及其关键中间体的合成方法
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5648511A (en) * 1990-11-19 1997-07-15 G.D. Searle & Co. Method for making intermediates useful in the synthesis of retroviral protease inhibitors
FR2676444B1 (fr) * 1991-05-16 1995-03-10 Sanofi Elf Nouveaux derives d'amino-3 pyridazines actifs sur le systeme nerveux central, procede de preparation et compositions pharmaceutiques en contenant.
GB9310713D0 (en) * 1993-05-24 1993-07-07 Zeneca Ltd Aryl substituted heterocycles
CZ284379B6 (cs) * 1994-04-19 1998-11-11 Neurosearch A/S Tropanové deriváty, způsob jejich přípravy a jejich použití
GB9523526D0 (en) * 1995-11-17 1996-01-17 Zeneca Ltd Therapeutic compounds
DE19546462A1 (de) * 1995-12-13 1997-06-19 Bayer Ag Diarylacetylenketone
WO1997024325A1 (en) * 1995-12-28 1997-07-10 Takeda Chemical Industries, Ltd. DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS
US6323206B1 (en) * 1996-07-12 2001-11-27 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
CA2259927A1 (en) * 1996-07-12 1998-01-22 Leukosite, Inc. Chemokine receptor antagonists and methods of use therefor
AU5604998A (en) * 1996-12-13 1998-07-03 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
WO1998025617A1 (en) * 1996-12-13 1998-06-18 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
AU8576098A (en) * 1997-07-25 1999-02-16 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
IL125658A0 (en) * 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
AR013669A1 (es) * 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos
EP1047675A1 (en) * 1998-01-21 2000-11-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US7217714B1 (en) * 1998-12-23 2007-05-15 Agouron Pharmaceuticals, Inc. CCR5 modulators
EP1013276A1 (en) 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
PE20001420A1 (es) * 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
KR100548854B1 (ko) * 2000-05-26 2006-02-02 화이자 인코포레이티드 Ccr5 조절제로서의 트리아졸릴 트로판 유도체

Also Published As

Publication number Publication date
EP1526134A3 (en) 2006-11-29
IS6565A (is) 2002-09-24
HUP0302474A3 (en) 2007-05-29
IL152531A (en) 2010-05-17
BRPI0110955B1 (pt) 2016-06-28
MY153023A (en) 2014-12-31
AP1965A (en) 2009-03-04
AU2001252482C1 (en) 2001-12-03
EA007580B1 (ru) 2006-12-29
AP2002002663A0 (en) 2002-12-31
SI1284974T1 (en) 2004-08-31
HK1054927A1 (en) 2003-12-19
BR0110955A (pt) 2003-06-03
CA2408909C (en) 2006-06-27
ATE407134T1 (de) 2008-09-15
CZ299102B6 (cs) 2008-04-23
NO2020019I1 (no) 2020-06-30
CN1279040C (zh) 2006-10-11
CA2408909A1 (en) 2001-11-29
KR20030004417A (ko) 2003-01-14
UY26727A1 (es) 2001-12-28
PL359267A1 (en) 2004-08-23
SI1526134T1 (sl) 2008-12-31
HK1090836A1 (en) 2007-01-05
LTPA2008004I1 (lt) 2020-07-27
DK1284974T3 (da) 2004-06-07
PT1284974E (pt) 2004-06-30
NO20025227L (no) 2002-10-31
TR200400541T4 (tr) 2004-04-21
PL200551B1 (pl) 2009-01-30
EP1526134B1 (en) 2008-09-03
CY1108451T1 (el) 2014-04-09
ES2401812T3 (es) 2013-04-24
KR100548854B1 (ko) 2006-02-02
PA8517101A1 (es) 2002-10-24
CN1680371A (zh) 2005-10-12
DE60135685D1 (de) 2008-10-16
HU225810B1 (en) 2007-10-29
TWI230160B (en) 2005-04-01
YU82202A (sh) 2005-11-28
BRPI0110955B8 (pt) 2021-05-25
NL300338I2 (nl) 2008-06-02
TNSN01077A1 (fr) 2005-11-10
EP1990341A1 (en) 2008-11-12
GEP20063799B (en) 2006-04-25
ME00555A (en) 2011-12-20
DZ3464A1 (da) 2001-11-29
ES2311126T3 (es) 2009-02-01
MY156920A (en) 2016-04-15
NO327892B1 (no) 2009-10-12
KR100523501B1 (ko) 2005-10-25
NO20025227D0 (no) 2002-10-31
WO2001090106A2 (en) 2001-11-29
PE20011371A1 (es) 2002-01-18
NL300338I1 (nl) 2008-05-01
NO2010007I1 (no) 2010-04-08
IL152531A0 (en) 2003-05-29
RS20090438A (en) 2010-05-07
SK16432002A3 (sk) 2004-01-08
CU23288B7 (es) 2008-06-30
LU91417I2 (fr) 2008-04-22
EP1284974B1 (en) 2004-03-03
FR08C0007I2 (fr) 2009-01-15
ATE260914T1 (de) 2004-03-15
HK1078573A1 (en) 2006-03-17
OA12264A (en) 2003-11-10
LTC1284974I2 (lt) 2020-11-10
NZ521477A (en) 2004-07-30
EE05110B1 (et) 2008-12-15
ES2215129T3 (es) 2004-10-01
JP2003534343A (ja) 2003-11-18
BG65966B1 (bg) 2010-07-30
EP1990341B1 (en) 2013-01-23
HRP20020938A2 (en) 2005-02-28
LU91417I9 (da) 2019-01-02
RS50904B (sr) 2010-08-31
HRP20020938B1 (en) 2011-05-31
PT1526134E (pt) 2008-10-28
EE200200656A (et) 2004-06-15
JP3693957B2 (ja) 2005-09-14
ME00555B (me) 2011-12-20
AU2001252482B2 (en) 2006-01-19
AR060159A2 (es) 2008-05-28
CY2008006I1 (el) 2009-11-04
HUP0302474A2 (hu) 2003-11-28
DE60102233T2 (de) 2005-01-27
EP1284974A2 (en) 2003-02-26
EP1526134A2 (en) 2005-04-27
SK286129B6 (sk) 2008-04-07
CR10145A (es) 2008-08-19
RS51436B (en) 2011-04-30
CY2008006I2 (el) 2009-11-04
WO2001090106A3 (en) 2002-03-28
MY131019A (en) 2007-07-31
JP2005194283A (ja) 2005-07-21
EA005382B1 (ru) 2005-02-24
CZ20023806A3 (cs) 2004-01-14
DE122008000011I1 (de) 2008-06-05
EA200401056A1 (ru) 2005-04-28
KR20050046743A (ko) 2005-05-18
NO2010007I2 (no) 2013-09-09
CN100355753C (zh) 2007-12-19
AR028622A1 (es) 2003-05-14
DE60102233D1 (de) 2004-04-08
JP4854970B2 (ja) 2012-01-18
EA200201141A1 (ru) 2003-04-24
BG107140A (bg) 2003-05-30
MA26902A1 (fr) 2004-12-20
FR08C0007I1 (da) 2008-04-25
IS2511B (is) 2009-05-15
AU5248201A (en) 2001-12-03
MXPA02011631A (es) 2003-03-27
CN1437599A (zh) 2003-08-20
EG24137A (en) 2008-08-06

Similar Documents

Publication Publication Date Title
DK1526134T3 (da) Triazolyltropanderivater som CCR5-modulatorer
NO20026195D0 (no) Substituerte-triazolopyrimidiner som anticancer midler
NO20013149D0 (no) Piperidiner som CCR5-modulatorer
NO20013183L (no) Azabicykloalkaner som CCR5-modulatorer
NO20013671L (no) Substituerte bisycliske derivater nyttige som anticancer midler
DK1492789T3 (da) Tropanderivater som CCR5-modulatorer
NO20031001D0 (no) Polyarylkarboksamider nyttige som lipidsenkende midler
DK1397364T3 (da) Hidtil ukendte pyrrolderivater som farmaceutiske midler
NO20021239D0 (no) Pteridinoner som kinase-inhibitorer
DK1326858T3 (da) Piperidinforbindelser som anti-allergiske midler
DK1244647T3 (da) Quinzolinderivater som VIGF-inhibitorer
NO20051042L (no) Pyrimidylsulfonamidderivater som kemokinreseptormodulatorer
NO20032531D0 (no) Tetralon-derivater som antitumormidler
NO20023828L (no) Pyrimidin-4-on derivater som LDL-PLA2 inhibitorer
NO20022888L (no) Lipopeptider som antibakterielle midler
NO20041317L (no) Benzimidazolidinondenvater som muskarine midler
NO20022887D0 (no) Lipopeptider som antibakterielle midler
NO20015065D0 (no) Pyrazolobenzodiazepiner som CDK2-inhibitorer
NO20032272D0 (no) Bifenylkarboksamider nyttige som lipidsenkende midler
NO20023770D0 (no) Indol-3-ylderivater
NO20035183D0 (no) 5-substituerte-2-arylpyridiner som CRF1 modulatorer
NO20040860L (no) Farmasoytisk sammensetning som innbefatter lumiracoxib
NO20021959D0 (no) Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer
NO20021251D0 (no) Tienoisoksazolyl- og tienylpyrrazolyl-fenoksysubstituerte propylderivater anvendelige som D4antagonister
NO20020457D0 (no) Benzenaminderivater som antikoagulanter